Lymphoma - Hodgkin lymphoma

The PBS subsidises brentuximab vedotin and pembrolizumab for patients with relapsed or refractory Hodgkin lymphoma.

Patient eligibility

The PBS subsidises treatment with brentuximab vedotin and pembrolizumab for patients with relapsed or refractory Hodgkin lymphoma. Patients must also have failed an autologous stem cell transplant (ASCT) or must be ASCT naïve. This is under section 100 under the National Health Act 1953, section 100 – Efficient funding of chemotherapy (EFC).

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits outlines restrictions for prescribing brentuximab vedotin and pembrolizumab.

Section 100 EFC arrangements

These items are only PBS subsidised for day admitted patients, non-admitted patients, or patients on discharge who are attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital (IV trastuzumab only).

These items are not PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Authority applications

Applying for initial treatment

Brentuximab – failed ASCT or is ASCT naïve

Apply for initial authority approval to prescribe PBS subsidised brentuximab vedotin for the treatment of failed ASCT or ASCT naïve relapsed or refractory Hodgkin lymphoma in writing and either:

All applications must include the completed:

Pembrolizumab

Apply for initial authority approval to prescribe PBS subsidised pembrolizumab for the treatment of relapsed or refractory Hodgkin lymphoma in writing and either:

All applications must include the completed:

Applying for continuing treatment

Apply for authority applications to prescribe continuing PBS subsidised brentuximab vedotin and pembrolizumab to treat relapsed or refractory Hodgkin lymphoma either:

Further information

Call the PBS Complex Drugs Programs enquiry line for further information.

Page last updated: 1 October 2020